TABLE 3.
Prestudy/Poststudy Change in All-Cause Direct Health Care Cost 180 Days Before and After ELX/TEZ/IVA New Initiation
| All-cause direct health care cost | 180-day preperiod | 180-day postperiod | Difference (% change) | P value |
|---|---|---|---|---|
| Total cost of care, mean (SD) | 58,180 (66,478) | 198,815 (68,220) | 241.7 | < 0.001 |
| Total medical benefit cost, mean (SD) | 28,764 (59,703) | 12,484 (51,826) | -56.6 | < 0.001 |
| Total pharmacy benefit cost, mean (SD) | 29,416 (25,860) | 186,331 (49,466) | 533.4 | < 0.001 |
| Total ELX/TEZ/IVA, cost mean (SD) | — | 156,629 (39,832) | — | — |
| Total inpatient hospitalization cost, mean (SD) | 16,771 (50,590) | 4,573 (39,470) | -72.7 | < 0.001 |
| Total emergency department cost, mean (SD) | 424 (2,356) | 248 (1,441) | -41.4 | 0.01 |
All members naive to cystic fibrosis transmembrane conductance regulator therapy and newly initiating ELX/TEZ/IVA. Costs are insurer allowed amounts, including network discounts and member share. Manufacturer did not offer ELX/TEZ/IVA rebates. Manufacturer patient assistance program discounts not included. All costs are shown in US dollars.
ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor.